The present invention relates to the discovery that co-administration of both oxytocin (OT) and at least one opioid antagonist can increase social function in a subject. In certain embodiments, the co-administration can be used to treat one or more social dysfunction disorders in a subject, including, but not limited to autism, schizophrenia, anxiety disorders, and post-traumatic stress disorder (PTSD). In other embodiments, the OT and the opioid antagonist can be co-administered to a subject as an aerosolized pharmaceutical composition.
Oxytocin and opioid antagonists for treatment of social dysfunction disorder
Olga Dal Monte;
2019-01-01
Abstract
The present invention relates to the discovery that co-administration of both oxytocin (OT) and at least one opioid antagonist can increase social function in a subject. In certain embodiments, the co-administration can be used to treat one or more social dysfunction disorders in a subject, including, but not limited to autism, schizophrenia, anxiety disorders, and post-traumatic stress disorder (PTSD). In other embodiments, the OT and the opioid antagonist can be co-administered to a subject as an aerosolized pharmaceutical composition.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
US11160843.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
4.43 MB
Formato
Adobe PDF
|
4.43 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.